Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1)

Fragment- and negative image-based screening of phosphodiesterase 10A inhibitors




Julkaisun tekijätJokinen E.M., Postila P.A., Ahinko M., Niinivehmas S., Pentikäinen O.T.

KustantajaWILEY

Julkaisuvuosi2019

JournalChemical Biology and Drug Design

Tietokannassa oleva lehden nimiCHEMICAL BIOLOGY & DRUG DESIGN

Lehden akronyymiCHEM BIOL DRUG DES

Volyymi94

Julkaisunumero4

Aloitussivu1799

Lopetussivun numero1812

Sivujen määrä14

ISSN1747-0277

eISSN1747-0285

DOIhttp://dx.doi.org/10.1111/cbdd.13584

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/42093050


Tiivistelmä
A novel virtual screening methodology called fragment- and negative image-based (F-NiB) screening is introduced and tested experimentally using phosphodiesterase 10A (PDE10A) as a case study. Potent PDE10A-specific small-molecule inhibitors are actively sought after for their antipsychotic and neuroprotective effects. The F-NiB combines features from both fragment-based drug discovery and negative image-based (NIB) screening methodologies to facilitate rational drug discovery. The selected structural parts of protein-bound ligand(s) are seamlessly combined with the negative image of the target's ligand-binding cavity. This cavity- and fragment-based hybrid model, namely its shape and electrostatics, is used directly in the rigid docking of ab initio generated ligand 3D conformers. In total, 14 compounds were acquired using the F-NiB methodology, 3D quantitative structure-activity relationship modeling, and pharmacophore modeling. Three of the small molecules inhibited PDE10A at similar to 27 to similar to 67 mu M range in a radiometric assay. In a larger context, the study shows that the F-NiB provides a flexible way to incorporate small-molecule fragments into the drug discovery.

Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Last updated on 2022-07-04 at 17:28